A Nomogram To Predict The Overall Survival Of Breast Cancer Patients And Guide The Postoperative Adjuvant Chemotherapy In China

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.v68.630207593
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–1792. doi:10.1056/NEJMoa05051816251534
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. doi:10.1016/S0140-6736(05)66544-015894097
   PubMed Web of Science ®Google Scholar
• Rossi L, Stevens D, Pierga JY, et al. Impact of adjuvant chemotherapy on breast cancer survival: a real-world population. PloS One. 2015;10:e0132853. doi:10.1371/journal.pone.013285326214853
   PubMed Web of Science ®Google Scholar
• Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360:2055–2065. doi:10.1056/NEJMoa081026619439741
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–444.22152853
   PubMed Web of Science ®Google Scholar
• Francescutti V, Farrokhyar F, Tozer R, et al. Primary tumor and patient characteristics in breast cancer as predictors of adjuvant therapy regimen: a regression model. Cancer Chemother Pharmacol. 2011;68:661–668. doi:10.1007/s00280-010-1532-521125276
   PubMed Web of Science ®Google Scholar
• Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–3734. doi:10.1200/JCO.2005.04.798516720680
   PubMed Web of Science ®Google Scholar
• Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from national surgical adjuvant breast and bowel project randomised clinical trials. Lancet. 2004;364:858–868. doi:10.1016/S0140-6736(04)16981-X15351193
   PubMed Web of Science ®Google Scholar
• Bedard PL, Cardoso F. Can some patients avoid adjuvant chemotherapy for early-stage breast cancer? Nat Rev Clin Oncol. 2011;8:272–279. doi:10.1038/nrclinonc.2011.1921364525
   PubMed Web of Science ®Google Scholar
• Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998;52:261–288. doi:10.1023/A:100614170322410066087
   PubMed Web of Science ®Google Scholar
• Wishart GC, Azzato EM, Greenberg DC, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12(1):R1. doi:10.1186/bcr246420053270
   PubMed Web of Science ®Google Scholar
• van ‘t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536. doi:10.1038/415530a11823860
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826. doi:10.1056/NEJMoa04158815591335
   PubMed Web of Science ®Google Scholar
• Bevilacqua JL, Kattan MW, Fey JV, et al. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol. 2007;25(24):3670–3679. doi:10.1200/JCO.2006.08.801317664461
   PubMed Web of Science ®Google Scholar
• Adjuvant! Online Web Site. Available from: http://www.adjuvantonline.com Accessed 121, 2018.
   Google Scholar
• Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19:980–991. doi:10.1200/JCO.2001.19.4.98011181660
   PubMed Web of Science ®Google Scholar
• Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol. 2005;23:2716–2725. doi:10.1200/JCO.2005.06.17815837986
   PubMed Web of Science ®Google Scholar
• Mook S, Schmidt MK, Rutgers EJ, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol. 2009;10:1070–1076. doi:10.1016/S1470-2045(09)70254-219801202
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Breast Cancer (Version 3. 2017). Available from: https://www.nccn.org/professionals/physician_gls/PDF/breast.pdf Accessed 121, 2018.
   Google Scholar
• Bray F, Ferlay J, Laversanne M, et al. Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration. Int J Cancer. 2015;137:2060–2071. doi:10.1002/ijc.2967026135522
   PubMed Web of Science ®Google Scholar
• Morabia A, Costanza MC. International variability in ages at menarche, first livebirth, and menopause. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol. 1998;148(12):1195–1205. doi:10.1093/oxfordjournals.aje.a0096099867266
   PubMed Web of Science ®Google Scholar
• Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–1886. doi:10.1093/jnci/81.24.18792593165
   PubMed Web of Science ®Google Scholar
• Bhoo-Pathy N, Yip CH, Hartman M, et al. Adjuvant! Online is overoptimistic in predicting survival of Asian breast cancer patients. Eur J Cancer. 2012;48:982–989. doi:10.1016/j.ejca.2012.01.03422366561
   PubMed Web of Science ®Google Scholar
• Yao-Lung K, Dar-Ren C, Tsai-Wang C. Accuracy validation of adjuvant! online in Taiwanese breast cancer patients-a 10-year analysis. BMC Med Inform Decis Mak. 2012;12:108. doi:10.1186/1472-6947-12-10822985190
   PubMed Web of Science ®Google Scholar
• de Glas NA, van de Water W, Engelhardt EG, et al. Validity of adjuvant! Online program in older patients with breast cancer: a population-based study. Lancet Oncol. 2014;15(7):722–729. doi:10.1016/S1470-2045(14)70200-124836274
   PubMed Web of Science ®Google Scholar
• Surveillance E, Results E. (SEER) Program Research Data (1973–2014), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. Available from: http://www.seer.cancer.gov Accessed 121, 2018.
   Google Scholar
• Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–2795. doi:10.1200/JCO.2009.25.652920404251
   PubMed Web of Science ®Google Scholar
• Allred DC, Carlson RW, Berry DA, et al. NCCN task force report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw. 2009;7:S1–S21. quiz S22-S23. doi:10.6004/jnccn.2009.0079
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB Sr. Evaluating discrimination of risk prediction models: the C statistic. JAMA. 2015;314:1063–1064. doi:10.1001/jama.2015.1108226348755
   PubMed Web of Science ®Google Scholar
• Chow E, Abdolell M, Panzarella T, et al. Predictive model for survival in patients with advanced cancer. J Clin Oncol. 2008;26:5863–5869. doi:10.1200/JCO.2008.17.136319018082
   PubMedGoogle Scholar
• Chow E, Ding K, Parulekar WR, et al. Predictive model for survival in patients having repeat radiation treatment for painful bone metastases. Radiother Oncol. 2016;118:547–551. doi:10.1016/j.radonc.2015.10.01826515411
   PubMed Web of Science ®Google Scholar
• Austin PC, McDonald KM. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 2009;29:661–677. doi:10.1177/0272989X0934175519684288
   PubMed Web of Science ®Google Scholar
• Korhonen T, Kuukasjarvi T, Huhtala H, et al. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. Breast. 2013;22:1119–1124. doi:10.1016/j.breast.2013.06.00123863867
   PubMed Web of Science ®Google Scholar
• Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–187. doi:10.1002/(ISSN)1097-01422910416
   PubMed Web of Science ®Google Scholar
• Song Q, Huang R, Li J, et al. The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China. PloS One. 2013;8:e72175. doi:10.1371/journal.pone.007217523977244
   PubMed Web of Science ®Google Scholar
• Agrup M, Stal O, Olsen K, et al. C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat. 2000;63:23–29. doi:10.1023/A:100649872150811079156
   PubMed Web of Science ®Google Scholar
• Jelovac D, Wolff AC. The adjuvant treatment of HER2-positive breast cancer. Curr Treat Options Oncol. 2012;13:230–239. doi:10.1007/s11864-012-0186-422410709
   PubMed Web of Science ®Google Scholar
• Stal O, Sullivan S, Wingren S, et al. C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer. 1995;31A:2185–2190. doi:10.1016/0959-8049(95)00344-48652240
   PubMed Web of Science ®Google Scholar
• Griggs JJ, Hawley ST, Graff JJ, et al. Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol. 2012;30:3058–3064. doi:10.1200/JCO.2012.41.956422869890
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gao H, Bu Y, et al. Factors associated with receipt of adjuvant chemotherapy among married women with breast cancer. World J Surg Oncol. 2013;11:286. doi:10.1186/1477-7819-11-28624175997
   PubMed Web of Science ®Google Scholar
• Brookhart MA, Schneeweiss S. Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results. Int J Biostat. 2007;3:14. doi:10.2202/1557-4679.1072
   PubMedGoogle Scholar
• Bosco JL, Silliman RA, Thwin SS, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63:64–74. doi:10.1016/j.jclinepi.2009.03.00119457638
   PubMed Web of Science ®Google Scholar